市場調査レポート

商品コード

1284233

がんワクチン市場の2028年までの予測- 製品タイプ別、技術別、用途別、エンドユーザー別、地域別の世界分析

Cancer Vaccines Market Forecasts to 2028 - Global Analysis By Product Type, Technology, Application, End users and By Geography

出版日: 2023年06月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 175+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,884円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 771,540円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 933,196円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,102,200円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.96円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のがんワクチン市場は、2022年に75億米ドルを占め、予測期間中に16.7%のCAGRで成長し、2028年には189億5,000万米ドルに達すると予想されています。

がんワクチンは、生物学的反応修飾物質として考えられている薬剤です。この生物学的反応修飾剤は、がんと闘うための身体の免疫システムの能力を高めることで機能します。がんワクチンには、治療用と予防用の2種類があります。健康な人のがんを予防するために、予防的ながんワクチンが使用されます。一方、がん患者さんには、がんと闘うための免疫力を高めるために、治療用がんワクチンを接種します。子どもから大人まで、がんワクチンを点滴で接種することができます。

世界がん研究基金（WCRF）の統計によると、2020年の世界のがん患者数は約1,810万人で、そのうち男性が930万人、女性が880万人となっています。

市場力学：

促進要因

主要な市場プレイヤー間の戦略的パートナーシップの拡大

この市場は、Merck &Co., Inc.やGSK plcなどの業界プレーヤーが新規ワクチンの導入に大きく注力していることが特徴です。しかし、製品承認の欠如や、新規ワクチンのパイプラインにおける治療適応症の不均衡により、大きな市場ギャップが懸念されています。さらに、新規がんワクチンの開発に取り組んでいる中小規模のバイオテクノロジー企業や学術機関は、資金や投資の獲得に苦労しています。そのため、国際市場へのアクセスや最先端の新製品を市場に提供するために、コラボレーションを促進する新しいビジネスモデルが採用されています。その結果、予防・治療用ワクチンの研究開発に携わる中堅免疫療法企業の多くは、現在、業界の有名企業と協力してワクチンの安全性と有効性を評価する臨床試験を実施しています。

抑制要因

個別化医療の進展に伴うがんワクチンの使用制限

世界の主要な死因の一つであるがんは、複雑で不均質な疾患です。治療用がんワクチンは、病気の根本的な原因ではなく、がん細胞を標的とするのに対し、予防用がんワクチンは、病気に対する身体の自然な防御を強化するように働きます。さらに、これらのワクチンは免疫療法の一種であり、世界的に製品承認を得ているがん種は限られています。一部のがん種（大腸がん、乳がん、非ホジキンリンパ腫）は、分子のサブタイプに基づき、さらに細かく分類されています。また、がんの部位やステージによって、同じ腫瘍内でも特定のマーカーがどのように発現しているかが異なります。これらのがんの予後を改善するためには、がんワクチンに加えて、より精密な治療法が必要です。腫瘍学の予防と治療に対する新しいアプローチとして、個別化医療または精密医療があります。腫瘍の発がん促進因子を標的とし、その環境に影響を与えるような方法で治療を変えることができるかもしれません。

機会

がんワクチンの臨床試験の拡大

PDAC（膵管腺がん）は、根治的な治療法がない膵臓がんの一般的な形態です。バイオエヌテックが開発したPDACに対するワクチンの臨床試験第1相のデータが公開されました。バイオエヌテックが開発したmRNAワクチン接種は、ネオアンチゲンの遺伝コードを患者の細胞に届けるために使用されます。このコードは、がん細胞が作り出すタンパク質であるネオアンチゲンを生成するよう細胞に指示します。これらのタンパク質は、免疫系が腫瘍を直接攻撃するのを助けるために作られます。

脅威

規制当局の承認に時間がかかること、開発コストが高いこと

がんワクチンの開発には高いコストがかかり、ワクチン製造には長い時間がかかるため、市場開拓は予測期間中に抑制されると予想されます。さらに、製品承認の欠如や、今後のワクチンのパイプラインにおける治療適応症の不均衡によって、市場の大きなギャップが脅かされています。

COVID-19の影響：

2020年1月30日、世界保健機関（WHO）は、COVID-19の発生を世界的に懸念される公衆衛生上の緊急事態と宣言しました。世界の合計210カ国がCOVID-19の影響を受けています。COVID-19の影響を受けたいくつかの国で閉鎖され、COVID-19の大流行後に病気のヘルスケアワーカーが増加し、不足が生じたため、がんワクチンを製造・販売する企業は、COVID-19による影響を最小限に抑えています。

予測期間中、クレアバックス分野が最大になると予想される

CreaVaxは予測期間中に大きく拡大すると予想されています。患者の末梢血単核細胞（PBMC）を用いて、腫瘍溶解液とKLHで感作した後に樹状細胞（Keyhole Limpet Hemocyanin）に成熟させる自家樹状細胞ベースのがんワクチンです。Creagene社は、腎細胞がんの治療用ワクチン「Creavax」を発売しました。肝細胞がんに対するCreaVaxの有効性は、現在、第III相臨床試験で検討中です。

予測期間中、成人用ワクチン分野のCAGRが最も高くなると予想される

成人用ワクチン市場セグメントは、最大の市場シェアを獲得しました。さらに、世界中の多くの研究者が、潜在的な治療戦略を実現するための効率的なワクチン候補を開発するために、綿密な研究を行っています。例えば、メリーランド州のNorthwest Biotherapeutics社は、2022年3月に、英国ソーストンの新しい生産施設において、膠芽腫の症例に対する治療として、先進治療薬を用いた初の個別化樹状細胞ベースのがんワクチンの生産を同情的な理由で開始することを発表する予定です。

最もシェアの高い地域

最も収益シェアが高かったのは、北米でした。予測期間中に市場を牽引する要因としては、がんの発生率の上昇、研究費の増加、市場参入企業による臨床試験の増加、がんワクチンに対する規制当局の承認などが挙げられます。例えば、米国がん協会は、2021年には米国で608,570人のがん死亡が発生し、190万人の新規がん患者が発生すると予測しています。一方、2022年にがんの診断を受けるアメリカ人は190万人に迫ると予想されます。2018年には乳がんが最も多いがん診断となり、推定287,850人の女性と2,710人の男性が罹患するとされています。男性で最も多く、全体で2番目に多いがん診断は、前立腺がんです。

CAGRが最も高い地域：

欧州の市場は大きく成長すると予想されます。これは、がんワクチンに対する需要の高まり、がんの罹患率の上昇、欧州各地のがん学会による調査研究への支援の増加、同地域の新興市場プレイヤーなどの要因が、樹状細胞がんワクチン市場に好影響を与えているためと考えられています。

主な発展：

2022年6月、バイオテクノロジー企業のTreos Bio Limitedは、転移性大腸がんの治療薬として、F. Hoffmann-La Roche AG製のpd-l1-inhibitorと併用するポリペピ1018の第2相試験で最初の患者が投与されたと発表しました。

2020年10月、臨床ステージのバイオ医薬品会社であるVaccibody ASが、ロシュグループの一員であるジェネンテック社と、がん治療のためのDNAベースの個別化ネオ抗原ワクチン（DNAがんワクチン）の開発および商業化に関する全世界でのライセンスおよびコラボレーション契約を締結したことを発表しました。

2020年6月、UbiVac, Inc.はブリストル・Bristol Myers Squibb社と、ユビバックの治験製品であるDPV-001と進行トリプルネガティブ乳がんに対する免疫療法との併用による安全性、忍容性、予備的有効性を評価する臨床試験提携を発表しました。

本レポートが提供するもの

地域レベルおよび国レベルセグメントにおける市場シェア評価
新規参入企業への戦略的提言
2020年、2021年、2022年、2025年、2028年の市場データを網羅
市場動向（促進要因、抑制要因、機会、脅威、課題、投資機会、推奨事項）
市場推定に基づく、主要ビジネスセグメントにおける戦略的提言
主要な共通トレンドをマッピングした競合情勢。
詳細な戦略、財務、最近の開発状況を含む企業プロファイル
最新の技術的進歩をマッピングしたサプライチェーン動向

無料のカスタマイズ提供：

本レポートをご購入いただいたお客様には、以下の無料カスタマイズオプションのいずれかを提供させていただきます：

企業プロファイル
- 追加市場プレイヤーの包括的なプロファイリング（最大3社まで）
- 主要プレイヤーのSWOT分析（3社まで）
地域別セグメンテーション
- お客様のご希望に応じて、主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる。）
競合ベンチマーキング
- 製品ポートフォリオ、地域的プレゼンス、戦略的提携に基づく主要プレイヤーのベンチマーキング

樹状細胞（DC）がんワクチン
組換えがんワクチン
全細胞がんワクチン
抗原/アジュバントがんワクチン
ウイルスベクターおよびDNAがんワクチン
サブユニットワクチン
結合型ワクチン
不活化ワクチン
弱毒化生ワクチン
その他の技術

第7章世界のがんワクチン市場：用途別

前立腺がん
子宮頸がん
その他の用途

第8章世界のがんワクチン市場：エンドユーザー別

小児科
大人
その他のエンドユーザー

第9章世界のがんワクチン市場：地域別

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章会社概要

Aduro Biotech Inc.
Advaxis Inc.
Amgen Inc.
Argos Therapeutics
Astellas Pharma Inc.
Astrazeneca Plc.
Batavia Bioservices,
Bristol-Myers Squibb Company
Csl Limited
Dandrit Biotech
Dynavax Technologies Corporation
Generex Biotechnology Corporation
Immunocellular Therapeutics, Ltd
Merck & Co., Inc.
Sanpower Corporation
Sanpower Group Co. Ltd.
Vaccinogen, Inc.

図表

List of Tables

Table 1 Global Cancer Vaccines Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 3 Global Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 4 Global Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 5 Global Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 6 Global Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 7 Global Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 8 Global Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 9 Global Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 10 Global Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 11 Global Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 12 Global Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 13 Global Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 14 Global Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 15 Global Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 16 Global Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 17 Global Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 18 Global Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 19 Global Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 20 Global Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 21 Global Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 22 Global Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 23 Global Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
Table 24 North America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
Table 25 North America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 26 North America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 27 North America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 28 North America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 29 North America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 30 North America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 31 North America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 32 North America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 33 North America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 34 North America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 35 North America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 36 North America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 37 North America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 38 North America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 39 North America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 40 North America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 41 North America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 42 North America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 43 North America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 44 North America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 45 North America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 46 North America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
Table 47 Europe Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
Table 48 Europe Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 49 Europe Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 50 Europe Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 51 Europe Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 52 Europe Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 53 Europe Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 54 Europe Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 55 Europe Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 56 Europe Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 57 Europe Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 58 Europe Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 59 Europe Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 60 Europe Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 61 Europe Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 62 Europe Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 63 Europe Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 64 Europe Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 65 Europe Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 66 Europe Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 67 Europe Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 68 Europe Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 69 Europe Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
Table 70 Asia Pacific Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
Table 71 Asia Pacific Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 72 Asia Pacific Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 73 Asia Pacific Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 74 Asia Pacific Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 75 Asia Pacific Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 76 Asia Pacific Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 77 Asia Pacific Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 78 Asia Pacific Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 79 Asia Pacific Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 80 Asia Pacific Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 81 Asia Pacific Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 82 Asia Pacific Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 83 Asia Pacific Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 84 Asia Pacific Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 85 Asia Pacific Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 86 Asia Pacific Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 87 Asia Pacific Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 88 Asia Pacific Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 89 Asia Pacific Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 90 Asia Pacific Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 91 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 92 Asia Pacific Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
Table 93 South America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
Table 94 South America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 95 South America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 96 South America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 97 South America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 98 South America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 99 South America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 100 South America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 101 South America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 102 South America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 103 South America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 104 South America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 105 South America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 106 South America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 107 South America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 108 South America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 109 South America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 110 South America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 111 South America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 112 South America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 113 South America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 114 South America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 115 South America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
Table 116 Middle East & Africa Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
Table 117 Middle East & Africa Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
Table 118 Middle East & Africa Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
Table 119 Middle East & Africa Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
Table 120 Middle East & Africa Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
Table 121 Middle East & Africa Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
Table 122 Middle East & Africa Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
Table 123 Middle East & Africa Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
Table 124 Middle East & Africa Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
Table 125 Middle East & Africa Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
Table 126 Middle East & Africa Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
Table 127 Middle East & Africa Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
Table 128 Middle East & Africa Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
Table 129 Middle East & Africa Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
Table 130 Middle East & Africa Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 131 Middle East & Africa Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
Table 132 Middle East & Africa Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
Table 133 Middle East & Africa Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
Table 134 Middle East & Africa Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
Table 135 Middle East & Africa Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
Table 136 Middle East & Africa Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
Table 137 Middle East & Africa Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
Table 138 Middle East & Africa Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)

Product Code: SMRC23065

According to Stratistics MRC, the Global Cancer Vaccines Market is accounted for $7.50 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Cancer vaccines are drugs that are thought of as biological response modifiers. These biological response modifiers work by boosting the body's immune system's capacity to combat cancer. There are two different kinds of cancer vaccines: therapeutic and preventative. In order to prevent cancer in healthy individuals, preventive cancer vaccines are used. In order to boost their immune systems ability to combat the disease, cancer patients receive therapeutic cancer vaccines. Children and adults alike can receive cancer vaccines intravenously .

According to statistics published by the World Cancer Research Fund (WCRF), there were about 18.1 million cancer cases worldwide in 2020, of which 9.3 million were males and 8.8 million females.

Market Dynamics:

Driver:

Growing strategic partnerships among major market players

The market is characterized by a significant focus on the introduction of novel vaccines by industry players like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses as well as academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business models that encourage collaboration are being adopted so that these players can access international markets and provide the market with cutting-edge new products. As a result, a number of mid-sized immunotherapy players involved in the research and development of prophylactic and therapeutic vaccines are now working with well-known companies in the industry to carry out clinical trials to gauge the safety and effectiveness of vaccines.

Restraint:

Limiting the use of cancer vaccines with personalized medicine advances

Cancer, one of the leading causes of death worldwide, is a complex and heterogeneous disease. Therapeutic cancer vaccines target the cancer cells rather than the disease's underlying cause, whereas preventive cancer vaccines work to bolster the body's natural defenses against the disease. Additionally, these vaccines are a form of immunotherapy that only has a small number of cancer types for which they have received global product approval. Based on their molecular subtypes, some cancer types (colon, breast, and non-Hodgkin's lymphoma) have even more detailed classifications. Additionally, the location or stage of the cancer affects how certain markers are expressed within the same tumor. In order to improve the prognosis for these cancer types, more precise treatment methods are required in addition to cancer vaccines. A new approach to prevention and treatment in oncology is personalized or precision medicine. It may alter treatment in ways that target the tumor's oncogenic drivers and influence its environment.

Opportunity:

The expansion of cancer vaccine clinical trials

PDAC, or pancreatic ductal adenocarcinoma, is a common form of pancreatic cancer for which there are no curative therapies. Data from the first phase of a clinical trial for BioNTech's PDAC vaccine against PDAC was made public. The mRNA vaccination developed by BioNTech is used to deliver the genetic code for the neoantigen to the patient's cells. The code instructs the cells to produce the neoantigens, proteins created by cancer cells. These proteins are produced to help the immune system attack the tumor directly.

Threat:

Lengthy regulatory approvals and high developing cost

Market growth is anticipated to be constrained during the forecast period due to the high cost of developing cancer vaccines and the prolonged time required for vaccine manufacturing. Additionally, a sizable market gap is threatened by a lack of product approvals and an imbalance of therapeutic indications in the pipeline of upcoming vaccines.

COVID-19 Impact:

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of global concern. A total of 210 countries around the world have been impacted by COVID-19. Due to closures in several COVID-19-affected countries and an increase in the number of sick healthcare workers following the COVID-19 pandemic, which resulted in a shortage, companies that manufacture and distribute cancer vaccines have only been minimally impacted by COVID-19.

The creavax segment is expected to be the largest during the forecast period

CreaVax is expected to expand significantly during the forecast period. The patient's peripheral blood mononuclear cells (PBMC) are used to make the autologous dendritic cell-based cancer vaccine, which is sensitized with tumor lysate and KLH before maturing into dendritic cells (Keyhole Limpet Hemocyanin). Creagene released Creavax, a therapeutic vaccine for renal cell carcinoma. The effectiveness of CreaVax in the treatment of hepatocellular carcinoma is currently being studied in a Phase III clinical trial.

The adult vaccines segment is expected to have the highest CAGR during the forecast period

The adult vaccine market segment had the largest market share. Additionally, a large number of researchers around the world are conducting in-depth research to develop efficient vaccine candidates to realize potential therapeutic strategies. For instance, Northwest Biotherapeutics of Maryland will announce in March 2022 the start of production of the first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK, using advanced therapy medicinal products for the treatment of a glioblastoma case on compassionate grounds.

Region with highest share:

The largest revenue share came from North America. The factors driving the market during the forecast period include the rising incidence of cancer, rising research expenditures, an increase in clinical trials by industry participants, and regulatory approvals for cancer vaccines. For instance, the American Cancer Society predicts that in 2021 there will be 608,570 cancer deaths in the United States and an estimated 1.9 million new cancer cases. In contrast, the number of Americans who will receive a cancer diagnosis in 2022 will be close to 1.9 million. Breast cancer will be the most common cancer diagnosis in 2018, affecting an estimated 287,850 women and 2,710 men. The most frequent cancer diagnosis in men and the second most frequent overall is prostate cancer.

Region with highest CAGR:

Europe's market is expected to grow significantly. This can be attributed to factors such as the rising demand for cancer vaccines, the rising incidence of cancer, the increase in support for research studies from cancer societies across Europe, and emerging market players in the area, all of which have a positive impact on the market for dendritic cell cancer vaccines.

Key players in the market:

Some of the key players in Cancer Vaccines market include Aduro Biotech Inc., Advaxis Inc., Amgen Inc., Argos Therapeutics, Astellas Pharma Inc., Astrazeneca Plc., Batavia Bioservices, Bristol-Myers Squibb Company, Csl Limited, Dandrit Biotech, Dynavax Technologies Corporation, Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Corporation, Sanpower Group Co. Ltd. And Vaccinogen, Inc.

Key Developments:

In June 2022, Treos Bio Limited, a biotechnology company, announced the first patient dosed in a phase 2 trial of polypepi1018 in combination with pd-l1-inhibitor manufactured by F. Hoffmann-La Roche AG for the treatment of metastatic colorectal cancer.

In October 2020, Vaccibody AS, a clinical-stage biopharmaceutical company, announced its worldwide license and collaboration agreement with Genentech, Inc., a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines (DNA cancer vaccines) for the treatment of cancers.

In June 2020, UbiVac, Inc. announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac's investigational product, DPV-001, in combination with Immunotherapy for Advanced Triple Negative Breast Cancer.

Product Types Covered:

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines

Technologies Covered:

Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Subunit Vaccines
Conjugate Vaccines
Inactivated Vaccines
Live Attenuated Vaccines
Other Technologies

Applications Covered:

Prostate Cancer
Cervical Cancer
Other Applications

End Users Covered:

Pediatrics
Adults
Other End users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Product Type

5.1 Introduction
5.2 Preventive Cancer Vaccines
5.3 Therapeutic Cancer Vaccines

6 Global Cancer Vaccines Market, By Technology

6.1 Introduction
6.2 Dendritic Cells (DC) Cancer Vaccines
6.3 Recombinant Cancer Vaccines
6.4 Whole-cell Cancer Vaccines
6.5 Antigen/Adjuvant Cancer Vaccines
6.6 Viral Vector & DNA Cancer Vaccines
6.7 Subunit Vaccines
6.8 Conjugate Vaccines
6.9 Inactivated Vaccines
6.10 Live Attenuated Vaccines
6.11 Other Technologies

7 Global Cancer Vaccines Market, By Application

7.1 Introduction
7.2 Prostate Cancer
7.3 Cervical Cancer
7.4 Other Applications

8 Global Cancer Vaccines Market, By End User

8.1 Introduction
8.2 Pediatrics
8.3 Adults
8.4 Other End Users

9 Global Cancer Vaccines Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Aduro Biotech Inc.
11.2 Advaxis Inc.
11.3 Amgen Inc.
11.4 Argos Therapeutics
11.5 Astellas Pharma Inc.
11.6 Astrazeneca Plc.
11.7 Batavia Bioservices,
11.8 Bristol-Myers Squibb Company
11.9 Csl Limited
11.10 Dandrit Biotech
11.11 Dynavax Technologies Corporation
11.12 Generex Biotechnology Corporation
11.13 Immunocellular Therapeutics, Ltd
11.14 Merck & Co., Inc.
11.15 Sanpower Corporation
11.16 Sanpower Group Co. Ltd.
11.17 Vaccinogen, Inc.